Lisanti Capital Growth, LLC Fibrogen Inc Transaction History

Lisanti Capital Growth, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 05, 2018	SELL	$56.3 - $67.25 $1.6 Million - $1.91 Million	-28,415 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$44.9 - $64.95 $1.28 Million - $1.85 Million	28,415 New	28,415 $1.78 Million
Q1 2018 May 15, 2018	SELL	$45.35 - $61.65 $537,397 - $730,552	-11,850 Closed	0 $0
Q4 2017 Feb 07, 2018	BUY	$41.95 - $60.1 $235,339 - $337,161	5,610 Added 89.9%	11,850 $562,000
Q3 2017 Nov 13, 2017	BUY	$33.4 - $53.9 $208,416 - $336,336	6,240	6,240 $336,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Lisanti Capital Growth, LLC, based on Form 13F filings with the SEC.

Stay updated on Lisanti Capital Growth, LLC with notifications on news.